Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURMOUNT-MMO: Tirzepatide for Reduction of Morbidity and Mortality in Adults With Obesity
2022-501744-15-00Phase 3Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 27
01
Overview
Phase 3, randomised, double-blind trial in obesity, Overweight and cardiac morbidity comparing Tirzepatide with Placebo (2 arms). Primary endpoint: Time to first occurrence of any component event of composite endpoint. Planned start Dec 2022; status: authorised.
02
Drugs
03
Conditions
obesityOverweightcardiac morbidity
Beyond the preview
Go deeper on 2022-501744-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501744-15-00.